The IBD SmartSelect Composite Rating for Doximity rose from 93 to 96 Wednesday.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's a good item to have on your checklist when looking for the best stocks to buy and watch.
Doximity is now out of buy range after clearing the 30.50 entry in a cup with handle.
Discover The 3 Keys To Successful Stock Investing
The stock has a 98 EPS Rating, meaning its recent quarterly and annual earnings growth tops 98% of all stocks.
Its Accumulation/Distribution Rating of C- shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
In Q2, the company reported 36% earnings-per-share growth. Top line growth climbed 20%, up from 17% in the prior report. That marks two quarters of rising growth.
Doximity earns the No. 1 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A and Waystar Holding are also among the group's highest-rated stocks.
